{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:21:56Z","timestamp":1790716916840,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijrobp.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T04:29:40Z","timestamp":1515212980000},"page":"1195-1203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment"],"prefix":"10.1016","volume":"100","author":[{"given":"Xiao-Tang","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhung T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuyTram N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Filka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Liau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Kaprealian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney B.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leia","family":"Nghiemphu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.01.001_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMoa1006312","article-title":"NF\u03baBIA deletion in glioblastomas","volume":"364","author":"Bredel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.onc.1208225","article-title":"Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme","volume":"24","author":"Yin","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib8","first-page":"4499","article-title":"Activity of bortezomib in glioblastoma","volume":"26","author":"Styczynski","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2008.08.050","article-title":"Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies","volume":"74","author":"Kubicek","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib10","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ijrobp.2007.11.068","article-title":"Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability","volume":"71","author":"Lai","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomized, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","article-title":"Pharmacokinetic, pharmacodynamics and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma","volume":"51","author":"Moreau","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib13","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in Neuro-Oncology Working Group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3171\/2013.7.JNS1323","article-title":"Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells\u2019 VEGF production and angiogenesis","volume":"119","author":"Bota","year":"2013","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib15","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1158\/1078-0432.CCR-11-0075","article-title":"Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis","volume":"17","author":"Unterkircher","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib16","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib17","doi-asserted-by":"crossref","first-page":"4647s","DOI":"10.1158\/1078-0432.CCR-07-0334","article-title":"Incorporating bortezomib into the treatment of lung cancer","volume":"13","author":"Davies","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: A North Central Cancer Treatment Group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.001_bib20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10637-013-9968-1","article-title":"Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner","volume":"31","author":"Vlachostergios","year":"2013","journal-title":"Invest New Drugs"}],"updated-by":[{"DOI":"10.1016\/j.ijrobp.2019.01.071","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000}}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618300014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618300014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T21:51:35Z","timestamp":1535147495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618300014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0360301618300014"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.001","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ijrobp.2019.01.071","asserted-by":"object"}]},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}